Regd. Office: "Zydus Corporate Park",
Scheme No. 63, Survey No. 536,
Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad - 382 481.

November 13, 2019

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai–400 001

Code: *532321*

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai–400 051

Code: *CADILAHC*

Re: Press Release

Dear Sir,

We are forwarding herewith a copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter / half year ended on September 30, 2019 the same may please receive in order.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

CADILA HEALTHCARE LIMITED AHMEDABAD

Encl.: As above

Zydus dedicated to life

Press Release

Press Release Press Release
Press Release
Press Release Press Release
Press Release Press Release

Zydus Cadila registers Total income from Operations of Rs. 3367 Cr., up 14% in Q2

Ahmedabad, November 13, 2019

For the second quarter ended September 30, 2019, Zydus Cadila reported total income from operations of Rs. 3367 cr., up by 14% on a y-o-y basis. Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 626 cr., while the Net profit for the quarter stood at Rs. 107 cr. which includes an impairment charge of Rs. 268 cr. towards Levorphanol intangibles on account of entry of a new competitor. Adjusted for this, the Profit After Tax for the quarter stood at Rs. 319 cr.

The company's India business which comprises human formulations, consumer wellness and animal health business posted sales of Rs.1430 cr., up by 24% on a y-o-y basis. The company's business in the US posted sales of Rs. 1450 cr., up by 10% on a y-o-y basis. During the quarter, the company launched 7 new products in the US. The company filed 8 additional ANDAs with the USFDA and received 6 ANDA approvals, during the quarter. The company's business in the emerging markets of Asia, Africa and Latin America grew by 8%.

Making progress in its research programme, during the quarter, the company completed EVIDENCES IV Phase II clinical trials of Saroglitazar Magnesium in patients with Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) as the molecule achieved the primary efficacy end-points. A statistically significant 44.39% reduction in ALT (alanine aminotransferase) was observed in patients treated with Saroglitazar Magnesium. The EVIDENCES IV NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 patients with NAFLD, including NASH across 20 clinical sites in the United States of America.

A presentation on Saroglitazar in NAFLD was presented at AASLD 2019 held at Boston which highlighted the statistical significance of Saroglitazar when compared to the placebo in primary endpoint. This paper was selected as one of the best NAFLD/NASH debriefs presented at the AASLD Conference.

The Company also initiated patient enrolment for EVIDENCES VII Phase II clinical trials for evaluating the effect of Saroglitazar Magnesium in the treatment of NAFLD in women with polycystic ovary syndrome (PCOS) during the quarter. The patients are being recruited across multiple clinical sites in the US and Mexico.

Making progress with its vaccine research programme, the Company received the marketing authorization in India from the DCGI for Measles and Rubella vaccine during the quarter. The Phase II/ III clinical trials for Pentavalent Vaccine were also completed and the Company

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878

received regulatory approval to initiate Phase I clinical trials for Recombinant Hepatitis E Vaccine. In a major breakthrough, the Company received the marketing authorization for TwinrabTM (RabiMabs) from the Drug Controller General of India. The novel biologic which is a first-of-its-kind next gen therapy, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis. The United States Food and Drug Administration (USFDA) has granted an orphan drug status to this candidate.

***